The Incidentaloma Economy
Monetizing ambiguity through borderline results
An "incidentaloma" is a mass or abnormality found incidentally during imaging performed for another reason. These findings are extraordinarily common—autopsy studies show most adults harbor benign nodules in their thyroids, adrenals, and other organs. Advanced screening finds these abnormalities in living people, creating a cascade of follow-up tests, monitoring, and anxiety. For luxury health services, incidentalomas represent both a genuine clinical challenge and a business model.
The Prevalence Problem
High-resolution imaging reveals abnormalities that were always present but previously invisible. Studies suggest that CT scans find "incidental" nodules in 15-30% of scans, depending on the body region and population. The vast majority are benign and would never have caused symptoms. But once found, they cannot be ignored.
This creates a feedback loop: find an abnormality, recommend follow-up, find more abnormalities, recommend more follow-up. Each test is individually justified. The cumulative effect is a patient under perpetual surveillance for conditions that may never matter.
Why It Matters for Luxury
The incidentaloma economy reveals a tension at the heart of luxury health services. Thoroughness—the defining feature of premium medicine—inevitably produces ambiguous findings. The question is whether this represents diligent care or manufactured worry. The answer depends heavily on whether patients genuinely understand, before scanning, that they're likely to find something—and that "something" is probably nothing.
Research
- Incidental Findings from Low-Value Screening and Resulting Cascades of Care — Yale Global Health Review examines how patients with incidental findings experience overdiagnosis and overtreatment that create an illusion of benefit while conferring harm — July 2024
- First Do No Harm in Responding to Incidental Imaging Findings (2024) — Medical Journal of Australia argues for conservative management approaches to reduce cascades of unnecessary testing — July 2024.
- Overdiagnosis in Low-Dose CT Lung Cancer Screening: Systematic Review (2025) — International Journal of Cancer meta-analysis finds considerable variability in overdiagnosis across subtypes and risk profiles, demonstrating need for risk-stratified protocols — February 2025.
- Incidental Findings in Lung Cancer Screening (2024) — MDPI Cancer journal reports that LDCT screening often detects incidental findings unrelated to primary screening, causing unnecessary anxiety and invasive procedures — July 2024.